There is a greater overall survival benefit for patients with recurrent urothelial cancer being treated with pembrolizumab versus chemotherapy, according to long-term results of the KEYNOTE-045 trial.
There is greater overall survival (OS) benefit for patients with recurrent urothelial cancer being treated with pembrolizumab versus chemotherapy, according to long-term results of a randomized trial.
During the 2018 Genitourinary Cancers Symposium, Joaquim Bellmunt, MD, PhD, of the Dana Farber Institute, presented results from a median follow-up of 27.7 months of the KEYNOTE-045 trial, which compared pembrolizumab versus the investigator’s choice of paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer as second-line treatment.
Between November 2014 and November 2015, 542 patients were enrolled in the trial. Participants were randomized 1:1 to the immunotherapy arm to receive 200 mg of pembrolizumab intravenously every 3 weeks, or to the chemotherapy arm to receive 1 of the following: 175 mg/m2 of paclitaxel every 3 weeks, 75 mg/m2 of docetaxel every 3 weeks, or 320 mg/m2 of vinflunin every 3 weeks.
The dual primary endpoints were OS and progression-free survival (PFS). Key secondary endpoints were objective response rate (ORR), duration of response, and safety. Tumors were assessed at week 9 and every 6 weeks following for a 1-year duration, and then were assessed every 12 weeks thereafter. PD-L1 status was also obtained; it was considered positive when more than 10% of tumor and immune cells showed PD-L1 expression.
In the pembrolizumab arm, 26 patients were able to complete 2 years of therapy, while none in the chemotherapy arm were able to do so. The researchers also saw 10 complete responses in the pembrolizumab arm, compared with 1 in the chemotherapy arm.
Following 27.7 months of follow-up, the median OS was 10.3 months for participants treated with pembrolizumab versus 7.3 months for participants treated with chemotherapy. The 12-month OS was 44.4% for the pembrolizumab arm compared to 29.8% in the chemotherapy arm; 24-month OS was almost doubled in the pembrolizumab arm, at 27% (compared to 14.3% in the chemotherapy arm).
At 24 months, 60.6% of participants in the chemotherapy arm received an immunotherapeutic agent, including those who received pembrolizumab as part of the crossover, according to Bellmunt.
Although there were no significant differences in PFS at 14 or 27.7 months of follow-up, the authors did see that the proportion of participants that remained progression free was greater in the pembrolizumab arm at 12 months (18.4% versus 9.5%) and at 24 months (12.5% versus 2.5%).
ORR was almost double in the pembrolizumab arm (21.1% versus 11%), and the pembrolizumab arm saw fewer adverse events compared with the chemotherapy arm.
“Pembrolizumab is the first immunotherapy to demonstrate superior survival over chemotherapy in patients with advanced urothelial carcinoma after failure of platinum-based therapy,” concluded Bellmunt. “This is level 1 evidence that supports the use of pembrolizumab as a standard of care for this patient population.”
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More